In the FLAURA trial, patients with metastatic EGFR-altered NSCLC treated with first-line osimertinib had a median overall survival of 38.6 months (95% CI, 34.5-41.8 months),2 leading the FDA to approve osimertinib as first-line therapy in 2018. This evidence concerns the gene EGFR and non-small cell lung carcinoma.